HALLE/SAALE, Germany, 15 March 2016 Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced its financial results for the twelve-month period ending 31 December 2015 prepared in accordance with German GAAP ("HGB") and, on a voluntary basis, in accordance with IFRS as endorsed by the European Union. The Annual Reports are available on the company website (http://www.probiodrug.de/investors/reports-and-presentations/).
